Model-based analysis of Gd-BOPTA-induced MR signal intensity changes in cirrhotic rat livers
- PMID: 17568274
- DOI: 10.1097/RLI.0b013e318036b450
Model-based analysis of Gd-BOPTA-induced MR signal intensity changes in cirrhotic rat livers
Abstract
Objective: To quantify the hepatic transport of the hepatobiliary contrast agent gadobenate dimeglumine (Gd-BOPTA) in rats with biliary cirrhosis of various severity degrees from magnetic resonance (MR) signal intensities using a population pharmacokinetic approach.
Materials and methods: MR signal intensity was recorded during the Gd-BOPTA perfusion of normal and cirrhotic isolated rat livers. Similar experiments were conducted with Gd-labeled Gd-BOPTA to quantify Gd-BOPTA content in liver, bile, and perfusate. All experimental data were analyzed together according to a population pharmacokinetic approach.
Results: A 6-compartment model developed from the radioactivity data adequately fit all MRI data when 4 image parameters were added to describe the relationship between the amount of contrast agent and the signal intensity. The model showed that entry of Gd-BOPTA into hepatocytes was decreased in cirrhotic livers when compared to normal livers.
Conclusions: Although the MR signal intensity is similar in normal and cirrhotic livers, the population pharmacokinetic approach developed in this study shows a decreased entry of Gd-BOPTA into cirrhotic hepatocytes.
Similar articles
-
Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.Radiology. 2003 Oct;229(1):119-25. doi: 10.1148/radiol.2291020726. Epub 2003 Aug 27. Radiology. 2003. PMID: 12944603
-
Direct evidence of the temperature dependence of Gd-BOPTA transport in the intact rat liver.Appl Radiat Isot. 2005 Jun;62(6):943-9. doi: 10.1016/j.apradiso.2004.11.002. Epub 2005 Jan 7. Appl Radiat Isot. 2005. PMID: 15799874
-
Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA.Invest Radiol. 2005 Nov;40(11):705-14. doi: 10.1097/01.rli.0000183053.08921.2b. Invest Radiol. 2005. PMID: 16230903
-
Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).Magn Reson Imaging Clin N Am. 1996 Feb;4(1):61-72. Magn Reson Imaging Clin N Am. 1996. PMID: 8673717 Review.
-
MR imaging of CNS tumors: are all contrast agents created the same?Neuroradiology. 2006 Apr;48 Suppl 1:3-8. doi: 10.1007/s00234-006-1463-3. Neuroradiology. 2006. PMID: 16699847 Review.
Cited by
-
Concentrations and pharmacokinetic parameters of MRI and SPECT hepatobiliary agents in rat liver compartments.Eur Radiol Exp. 2021 Sep 21;5(1):42. doi: 10.1186/s41747-021-00236-y. Eur Radiol Exp. 2021. PMID: 34545428 Free PMC article.
-
Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.World J Gastroenterol. 2016 Jan 7;22(1):72-88. doi: 10.3748/wjg.v22.i1.72. World J Gastroenterol. 2016. PMID: 26755861 Free PMC article. Review.
-
Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.Eur Radiol. 2012 Mar;22(3):642-53. doi: 10.1007/s00330-011-2302-4. Epub 2011 Oct 9. Eur Radiol. 2012. PMID: 21984449
-
Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases.Radiat Oncol. 2010 May 27;5:44. doi: 10.1186/1748-717X-5-44. Radiat Oncol. 2010. PMID: 20507615 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical